A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
ENROLLING_BY_INVITATION
Status
Conditions
- Non Small Cell Lung Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Cancer
- Triple Negative Breast Cancer (TNBC)
- Urothelial Carcinoma Bladder
- Gastroesophageal Junction (GEJ) Adenocarcinoma
- Esophageal Squamous Cell Cancer
- Gastric Cancer
- Cancer
- Solid Tumors (Phase 1)
Interventions
- DRUG: RNDO-564
- DRUG: Pembrolizumab
Sponsor
Rondo Therapeutics